- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
NANOBIOTIX Presents First Data from Randomized Lung Cancer Trial
Biotech company shares results from Phase 2 clinical study at European conference.
Mar. 30, 2026 at 10:56am
Got story updates? Submit your updates here. ›
NANOBIOTIX, a late-stage biotechnology company, has announced the presentation of first data from a randomized Phase 2 clinical trial of its nanotherapeutic approach for treating lung cancer. The data was presented by Johnson & Johnson at the 2026 European Lung Cancer Conference.
Why it matters
NANOBIOTIX's nanotherapeutic technology aims to expand treatment options for cancer patients by enhancing the effectiveness of radiation therapy. The presentation of these early-stage clinical results is an important milestone for the company as it works to develop innovative solutions in the fight against lung cancer.
The details
The randomized Phase 2 clinical trial is evaluating NANOBIOTIX's lead product candidate, a nanoparticle-based therapy, in combination with radiotherapy for the treatment of non-small cell lung cancer. The data presented at the European conference provides initial insights into the safety and efficacy of this novel approach.
- The data was presented on March 30, 2026 at the 2026 European Lung Cancer Conference.
The players
NANOBIOTIX
A late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment options for cancer patients.
Johnson & Johnson
A multinational pharmaceutical and medical devices company that presented the data from NANOBIOTIX's clinical trial at the European Lung Cancer Conference.
What they’re saying
“We are excited to share these initial results from our randomized Phase 2 trial, which represent an important milestone in the development of our nanotherapeutic approach for lung cancer.”
— Laurent Levy, CEO, NANOBIOTIX
What’s next
NANOBIOTIX plans to continue the Phase 2 clinical trial and provide further updates on the study's progress in the coming months.
The takeaway
NANOBIOTIX's presentation of early-stage clinical data for its novel nanotherapeutic approach to lung cancer treatment highlights the company's commitment to developing innovative solutions that could potentially improve outcomes for patients.
